Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1645 1646
This examiner grants 45% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18278377 | CONDITIONAL DEGRADATION OF PROTEINS THAT ARE LOCALIZED AT THE PLASMA MEMBRANE | Non-Final OA | The Regents of the University of California |
| 17251287 | SINGLE-CHAIN BISPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | Final Rejection | The Regents of the University of California |
| 18297099 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | Non-Final OA | Eli Lilly and Company |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Non-Final OA | NOVARTIS AG |
| 18273796 | BLUE-GREEN ALGAE-CONTAINING TABLET | Non-Final OA | DIC Corporation |
| 18533714 | BISPECIFIC ANTI-CCL2 ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18280970 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF MYASTHENIA GRAVIS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18261483 | MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME | Final Rejection | Washington University |
| 18275616 | ANTI-IL1RAP ANTIBODIES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18550739 | CD160 Binding Domain | Non-Final OA | UCL BUSINESS LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy